Long‐term complete remission and peripheral biomarkers in Hodgkin lymphoma patients after decitabine‐plus‐camrelizumab epi‐immunotherapy and treatment cessation

Long‐term complete remission and peripheral biomarkers in Hodgkin lymphoma patients after decitabine‐plus‐camrelizumab epi‐immunotherapy and treatment cessation

Abstract Patients with relapsed/refractory classical Hodgkin lymphoma (cHL) achieve complete response (CR) after decitabine‐plus‐camrelizumab therapy, while long‐term outcome especially after treatment discontinuation remains unclear. We present a retrospective analysis of 87 relapsed/refractory cHL...

Full description

Bibliographic Details
Main Authors: Chunmeng Wang, Yuting Pan, Yang Liu, Bing Guo, Jinhong Shi, Guanghua Rong, Zhipeng Guo, Zhifang Li, Qingming Yang, Jing Nie, Weidong Han
Format: Article
Language:English
Published: Wiley 2023-12-01
Series:MedComm
Subjects:
biomarkers
classical Hodgkin lymphoma
decitabine‐plus‐camrelizumab
long‐term remission
relapse‐free survival
treatment discontinuation
Online Access:https://doi.org/10.1002/mco2.428

Internet

https://doi.org/10.1002/mco2.428

Similar Items